Valeant Pharmaceuticals said U.S. regulators have raised concerns over a new eye drop manufactured at a Bausch + Lomb facility in Florida. » Read More
Hedge fund manager Bill Ackman is parting company with the man who introduced him to his bad investment in Valeant Pharmaceuticals.
Wall Street's top dogs partied the night away at the 2016 Robin Hood benefit Monday night in New York City, and raised money for a worthy cause.
Shares of Zoetis fell Tuesday following a New York Times report that billionaire hedge fund manager Bill Ackman is paring his stake.
The activist investor and founder of Pershing Square Capital will sell nearly 17 million shares in the animal health company.
Some of the names on the move ahead of the open.
His Pershing Square Capital has had a difficult year, particularly over its stake in Valeant, the drug company that has come under intense scrutiny.
Bill Ackman and David Einhorn are two of the most well-known top hedge fund managers, but they might as well be on a seesaw.
If you can't charge "hundreds of thousands" of dollars a year for drugs, will there be drugs for orphan diseases?
Beset by market volatility, crowded into similar strategies and bogged down by huge piles of investment capital, hedge funds are struggling this year.
Hedge fund manager Bill Ackman took more swipes at Herbalife, saying he has not changed his bet against the nutritional company.
Hedge fund manager Bill Ackman defended his key holding Valeant Pharmaceuticals on Monday, as its shares continued to tumble.
The hedge fund manager says he aims to bring a "meaningful" turnaround and touted embattled drugmaker Valeant's new chief executive.
Discussing shining the spotlight on Herbalife, with Bill Ackman, Pershing Square Capital CEO and portfolio manager.
Warren Buffett vigorously defended his long-standing investment in Coca-Cola, rejecting critics who say the company's drinks are harmful.
Einhorn took a bruising in the markets last year, but at least one of his apparent strategies is now paying off handsomely.
Bill Ackman, Pershing Square, testifies before the US Senate to discuss his relationship with Valeant Pharmaceuticals.
Hedge funds are getting killed, says hedge fund manager Dan Loeb.
Hedge fund titan Bill Ackman is best known for his investments in the market, but it's another investment that's grabbing the attention of Wall Street.
Hedge funds have suffered their worst quarter in seven years after more than $15 billion was pulled out by investors, the Financial Times reports.
Traders seem encouraged by the recent bout of Chinese economic data. They may be wrong.